

Zhou, Alan (Lei) Shanghai

Life Science & Healthcare

Compliance & Risk Control

Corporate / Merger & Acquisition

Private Equity & Investment Funds

Environment, Social & Governance (ESG)



Direct: 86-21-2310-8200

Telephone: 86-21-2310-8288

Fax: 86-21-2310-8299

Email: alanzhou@glo.com.cn

Practice Areas

Alan Zhou's practice is focused in the areas of mergers & acquisitions, private equity/venture capital, regulatory compliance, and general corporate. Mr. Zhou has a particularly strong background in pharmaceutical and healthcare industrial sectors.

Mr. Zhou has represented many multinational corporations, reputable Chinese state owned and private corporations, and private equity/venture capital funds. He has routinely represented such multinational corporations as Sanofi, Schlumberger, Siemens, Boehringer Ingelheim, Novartis, Aon, Bureau Veritas, Catalent, Terumo, Tosoh, Barclays, Societe Generale Bank, Samsung and SK Telecom. Mr. Zhou has not only worked for reputable Chinese private companies such as Focus Media, VIPShop, Acorn International, Hisoar Pharmaceutical, Tianyuan Biopharm, and GeneScience Pharma, he has also advised PRC state owned companies such as Shanghai Dasheng, Shanghai Industrial and Shanghai Airport Authority. In the area of PE/VC, Mr. Zhou has acted for CBRE Investors, Colony Capital, Navis Capital, Lightspeed Ventures, Qiming Ventures, DT Capital, NEA, New Alliance Capital, Warden International, WINS and other international and local PE/VC funds.

Work Experience

Mr. Zhou has been seconded as general counsel for China operations of Boehringer Ingelheim, a leading multinational pharmaceutical company, for more than nine years, and is responsible for various legal matters including general corporate, acquisitions and joint venture formation, compliance and regulatory, intellectual property and corporate restructuring.

Education

China Europe International Business School Executive MBA
College of Law, Shanghai International Studies University L.L.B.

Awards

Mr. Zhou has been ranked as a Tier 1 Lawyer in the Healthcare field, and as a leading lawyer in M&A and Capital Market by Chambers & Partners in 2012, 2013 and 2014.

He has also been identified as a leading legal expert in Corporate/ M&A in China by Asialaw Leading Lawyers 2014, and as a leading practitioner in M&A by the Guide to Leading Practitioners (Legal Media Group) 2013.

Associations and Memberships

Mr. Zhou is the standing director of CEIBS Alumni Healthcare Association and is also an investment partner of HGI FINAVES China Fund.

Languages

Chinese, English

Insights

Navigating the "Look-Through" Mechanism - New Challenges under the 2025 Medical Products Price & Procurement Credit...
2026-03-06

Thomson Reuters invited GLO to write Commercialization of Healthcare Global Guide 2021, China Chapter
2022-01-19

Analysis on Bribe-Taking Parties under the FCPA and China's Anti-Corruption Laws
2021-06-29

How would the Data Security Law Impact Cross-Border Compliance Investigations and Litigations?
2021-06-28

GLO Authors China Chapter for Chambers Life Sciences 2020 Guide
2020-04-09

Are Private FCPA Investigations Still Doable in China?
2019-04-17

Impact of CFDA's New Regulation on Imported Drug Registration
2017-04-01

Bribery watch: draft Anti-unfair Competition Law cracks whip
2016-03-11

Key Points of The Interim Administrative Measures for the List of Dishonest Enterprises Committing Grave Illegalties
2016-01-06

Case Study: Horizontal Monopoly Agreement Conducted by Auto Parts Manufacturers and Bearing Manufacturers
2014-09-15

The Registration System Reform for Company's Registered Capital
2014-04-02

Shanghai Gold Association and Gold Retailers Price Monopoly Case
2014-04-01

News updates

Awards & Rankings | Alan Zhou and Kunlin Wang Honored as LEGALBAND Client Choice: Top 15 in Compliance Versatile P...
2020-08-07

Awards & Rankings | GLO Honored in LEGALBAND 2020
2020-04-14

Awards & Rankings | GLO Honored in Legal 500 Asia-Pacific Rankings 2020
2020-01-16

Awards & Rankings | GLO Honored in Chambers Asia-Pacific Rankings 2020
2019-12-05

Awards & Rankings | GLO Awarded Numerous Honors in The Legal 500 Asia-Pacific 2019
2019-01-16

Awards & Rankings | GLO Awarded Numerous Honors in Chambers Asia-Pacific 2019 Guide
2018-12-03

GLO helps the Restructure of China Operation of Siemens Healthineers for its successful debuts on the Frankfurt Stock Exc...
2018-03-19

Awards & Rankings | GLO Ranked as Leading Law Firm by Chambers Asia-Pacific 2018
2017-12-12

Awards & Rankings | GLO's 36 Lawyers Recommended by The Legal 500 2018 Ranking
2017-12-04

Awards & Rankings | GLO Ranked Leading Law Firm by Asialaw Profiles 2018
2017-11-14

GLO Represents BeiGene in a Mega Deal in China Biopharma
2017-09-06

Awards & Rankings | GLO Ranks Top Tier PRC Law Firm by Chambers China (2015 Edition)
2015-02-28

Awards & Rankings | Our partners are recognized by Asia Law & Practice as Asialaw Leading Lawyers in China in the fields...
2014-05-28

Awards & Rankings | GLO Ranks Top Tier PRC Law Firm by Chambers China in 2014 Edition
2014-03-06

Awards & Rankings | GLO Ranks Top Tier PRC Law Firm by Chambers China in 2013
2013-12-19

ALB Hong Kong In-house Legal Summit 2013
2013-09-18

GLO represents Boehringer Ingelheim in the first biopharmaceutical Contract Manufacture Organization (CMO) project in C...
2013-06-17

Awards & Rankings | GLO Ranks Top Tier PRC Law Firm by Chambers China in 2013
2013-03-25

Global Partners Give Presentation in Lexis Nexis Annual Corporate Compliance Conference 2011
2011-07-21

GLO Assists Boehringer Ingelheim in the Establishment of its China Holding Company
2011-04-26

GLO Completes the Novartis's Acquisition of Zhejiang Tianyuan in Human Vaccine Industry
2011-04-26

ALB Shanghai In-house Legal Summit 2010

